Bleomycin induced pulmonary fibrosis -a powerful preclinical tool for the evaluation of anti-fibrotic therapeutics.

🫁 Idiopathic Pulmonary Fibrosis (IPF) remains one of the most devastating chronic lung diseases, driven by complex dysregulated pathways involving multiple cell types, including macrophages, fibroblasts, and epithelial cells. Characterized by progressive lung inflammation and scarring, IPF continues to present significant challenges for patients due to limited therapeutic options.

💊Advancing effective anti-fibrotic therapies requires reliable and translational preclinical models that can accurately capture disease biology and support robust efficacy evaluation before clinical development.

The bleomycin-induced IPF mouse model developed in Biomedcode integrates comprehensive histopathological and molecular readouts of fibrosis and inflammation, providing a well-established and highly translational in vivo preclinical platform for evaluating novel therapeutics targeting fibrosis.